52 results about "Atropisomer" patented technology

Atropisomeric energy-transfer dye compounds are disclosed. A variety of molecular biology applications utilize atropisomeric xanthene fluorescent dyes as labels for substrates such as nucleotides, nucleosides, polynucleotides, polypeptides and carbohydrates. Methods include DNA sequencing, DNA fragment analysis, PCR, SNP analysis, oligonucleotide ligation, amplification, minisequencing, and primer extension.

An isomer-mixture metal complex composition that includes a plurality of atropisomers is described. This isomer-mixture metal complex composition is a metal complex composition which is a mixture of isomers each comprising a metal atom and a plurality of ligands, and is characterized by containing a plurality of atropisomers because at least one of the ligands has an aromatic ring as a substituent and the free rotation of the axis of the bonding between the aromatic ring and the ligand is inhibited by the formation of a complex of the metal atom with other ligand(s). An organic EL element using the isomer-mixture metal complex composition as a material for organic EL element is also described. Further, an illuminator and a display device which are obtained using the organic EL element are described.

Atropisomeric energy-transfer dye compounds are disclosed. A variety of molecular biology applications utilize atropisomeric xanthene fluorescent dyes as labels for substrates such as nucleotides, nucleosides, polynucleotides, polypeptides and carbohydrates. Methods include DNA sequencing, DNA fragment analysis, PCR, SNP analysis, oligonucleotide ligation, amplification, minisequencing, and primer extension.

The invention relates to a KRAS G12C inhibitor and application thereof, and particularly provides a compound shown as a formula (I), or a stereoisomer, or a resistance isomer, or a pharmaceutically acceptable salt, or a tautomer, or a prodrug thereof.

Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives having the general formula wherein R, R1, R2, R3, R4 and R5, are as defined herein, or a non-toxic pharmaceutically acceptable salt, solvate or prodrug thereof. The atropisomers can modulate the large conductance calcium-activated K+ channels and are useful in the treatment of disorders which are responsive to the opening of the potassium channels. In addition, the atropisomers can be stable, i.e., do not interconvert, for periods of up to one month, or more.

The invention discloses synthesis for chiral polyester containing binaphthyl. A binaphthyl compound is a common atropisomer compound with a C3 chiral axis. The axis of a binaphthyl structure is in an asymmetrical, multifunctional and stable chiral form, so that molecules and copolymers constructed by binaphthyl have superior structures and properties and wide application prospects in the field of materials. The patent is developed mainly around the synthesis of novel chiral polyester containing binaphthyl. A method for preparing the chiral polyester comprises the following steps of: synthesizing binaphthol or dinaphthyline by taking 2-naphthol or 2-naphthylamine as a raw material, and splitting to obtain chiral binaphthol or dinaphthyline; making dinaphthyline react with halohydrinare to obtain diol containing dinaphthalene radial, and react with the diacid to obtain chiral polyester; and making naphthidine react with chloride acyl chloride, hydrolyzing to obtain diol containing binaphthyl, and reacting with diacid to obtain chiral polyester containing binaphthyl. In the preparation of the chiral polyester, diol or diacid containing binaphthyl is prepared firstly, and then the chiral polyester is prepared by reacting. At last, the prepared chiral polyester is applied to molecular recognition.

The present invention relates to compounds which are perylenequinone derivatives, their stereoisomers and atropisomers. These compounds can be particularly useful as photosensitizers or sononsensitizers in photodynamic or sonodynamic therapy. The invention also relates to various methods for using these compounds in photodynamic and / or sonodynamic therapy. The compounds also are useful as therapeutic agents for treating various hyperproliferative disorders.

The invention relates to the use of the following anthracene derivatives as anti-infectives, preferably against multiply drug-resistant pathogens: (2R,3S,10R)-2,3,5,10-tetrahydroxy-6-methoxy-3-methyl-1,2,3,4,4a,9a-hexahydro-9H,10H-anthracen-9-one (tetrahydroaltersolanol B), (1R,2R,3R,4aS,9aR,10R)-1,2,3,5,10-pentahydroxy-7-methoxy-2-methyl-1,2,3,4,4a,9a-hexahydro-9H,10H-anthracen-9-one (altersolanol K), (2R,3R,4R,4aS,9aS,10R)-2,3,4,8,10-pentahydroxy-6-methoxy-3-methyl-1,2,3,4,4a,9a-hexahydro-9H,10H-anthracen-9-one (altersolanol L), 8-(1,7-dihydroxy-6-methyl-3-methoxy-9,10-dioxo-9H,10H-anthracen-2-yl)(1S,2S,3R,4S)-1,2,3,4,5-pentahydroxy-7-methoxy-2-methyl-1,2,3,4-tetrahydro-9H,10H-anthracene-9,10-dione (atropisomers alterporriol G and H); and (2R,3S,4aS,9aS,10R)-2,3,5,8,10-pentahydroxy-6-methoxy-3-methyl-1,2,3,4,4a,9a-hexahydro-9H,10H-anthracen-9-one (8-hydroxytetrahydroaltersolanol B).

The present invention relates to novel fused Imidazobenzothiazole derivatives, their pharmaceutically acceptable salts, and their isomers, steroisomers, atropisomers, conformers, tautomers, polymorphs, hydrates, solvates and N-oxide. The present invention also encompasses pharmaceutically acceptable compositions of said compounds and process for preparing novel compounds. The invention further relates to the use of the above-mentioned compounds for the preparation of medicament for use as pharmaceuticals.

The invention relates to two novel substances, namely (1R,2S,3S,4R)-3-acetoxy-1,2,4,5-tetrahydroxy-7-methoxy-2-methyl-1,2,3,4-tetrahydroanthracene-9,10-dione (3-O-acetyl altersolanol M)and 8-(4,5,6-trihydroxy-7-methyl-2-methoxy-9,10-dioxo-9H,10H-anthracen-1-yl)-(1S,2S,3R,4S)-1,2,3,4,5-pentahydroxy-7-methoxy-2-methyl-1,2,3,4-tetrahydro-9H,10H-anthracene-9,10-dione (the atropisomers alterporriol I and J)to their use as anti-infectives and as anti-cancer agents, as well as to methods of producing the same.

The present invention provides compounds of Formula (I),wherein:as defined in the specification, an enantiomer, diastereomer, atropisomer thereof, or a mixture thereof, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough, or itch. Also provided are pharmaceutical compositions containing compounds of the present invention.

The present invention relates to novel pyridinium compounds, their isomers, steroisomers, atropisomers, conformers, tautomers, polymorphs, hydrates and solvates. The present invention also encompasses process for preparing novel compounds and pharmaceutical composition of said compounds. The invention further relates to the use of the above mentioned compounds for the preparation of medicament for use as pharmaceuticals.

The present invention comprises a compound for the prevention and / or treatment of cardiovascular diseases, nephropathy, fibrosis, primary aldosteronism or edema. The compound is of the following general formula (I): wherein R1 represents a C1-C3 alkyl group; R2 represents a hydroxy-C1-C4 alkyl group and the like; R3 represents a halogeno group, a halogeno-C1-C3 alkyl group and the like; R4 represents a hydrogen atom, a halogeno group and the like, —R5 represents a sulfamoyl group or a C1-C3 alkylsulfonyl group; R6 represents a hydrogen atom, a halogeno group and the like] or an N-oxide, atropisomer of the foregoing, or pharmaceutically acceptable salt of the foregoing.

The present invention provides compounds of Formula (I),wherein:as defined in the specification, an enantiomer, diastereomer, atropisomer thereof, or a mixture thereof, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough, or itch. Also provided are pharmaceutical compositions containing compounds of the present invention.

The invention provides a series of conformationally stable kinase inhibitors, and methods of using the kinase inhibitors. The effect of atropisomerism on kinase selectivity was assessed, finding improved selectivity compared to rapidly interconverting parent compounds.

The present invention relates to atropisomers, solid forms, salt forms and deuterated derivatives of the ATM inhibitor 8-(1,3-Dimethyl-1H-pyrazol-4-yl)-1-(3-fluoro-5-methoxy- pyridin-4-yl)-7-methoxy-3-methyl-1,3-dihydroimidazo[4,5-c]quinolin-2-one as well as compositions thereof. The stable atropisomers do not interconvert and are represented by the following formulae: Compound1, Compound2.

The invention relates to a pharmaceutical liposomal composition comprising 2-{[5-{3-chloro-2-methyl-4-[2-(4-methylpiperazin-1-yl)ethoxy]phenyl}-6-(4-fluorophenyl)thieno [2,3-d]pyrimidin-4-yl]oxy}-3-(2-{[2-(2-methoxyphenyl)pyrimidin-4-yl]methoxy}phenyl) propanoic acid, referred to herein as ‘Compound A’, or a pharmaceutically acceptable salt thereof. More specifically the invention relates to a liposomal vehicle, an organic concentrate composition comprising Compound A, and a pharmaceutical composition for parenteral administration comprising liposomes and Compound A. Furthermore, the invention relates to the use of such compositions for the treatment of cancer. ‘Compound A’ as used herein includes all enantiomers, diastereoisomers, and atropisomers thereof, or mixtures thereof, and also optionally includes the pharmaceutically acceptable salts thereof.

The present invention relates to novel indanyl urea derivatives, their pharmaceutically acceptable salts, and their isomers, stereoisomers, atropisomers, conformers, tautomers, polymorphs, hydrates and solvates. The present invention also encompasses process for preparing novel compounds and pharmaceutical composition of said compounds. The invention further relates to the use of the compounds for the preparation of medicament for use as pharmaceuticals.

The invention provides a series of conformationally stable and selective kinase inhibitors, and methods of using the kinase inhibitors. The effect of atropisomerism on kinase selectivity was assessed, finding improved selectivity compared to rapidly interconverting parent compounds. The compounds herein are atropisomers having increased kinase selectivity, and are for use in treating conditions that benefit from selective kinase inhibition.

The present disclosure relates to a compound or a pharmaceutically acceptable salt, hydrate, solvate, N -oxide, stereoisomer, diastereoisomer, enantiomer, atropisomer, dimer, or polymorph for use in medicine comprising the following formula (I) shown in the specification, wherein R1, R2 and R3 are independently selected from each other; R1 is selected from an aryl, or heterocyclic ring; R2 is selected from H, alkyl, aryl, alcoxyl, halogen, hydroxyl, amine, carbonyl, or a heterocyclic ring; R3 is selected from H, or (II).

Provided herein are methods of altering enantiomeric excess. The methods may include irradiating an atropisomer that includes at least one chiral substituent to alter the enantiomeric excess of the atropisomer. The at least one chiral substituent may be removed following irradiation.

The present invention provides a cyclobutyl dihydroquinoline sulfonamide compound of Formula (I), an enantiomer, diastereoisomer, atropisomer thereof, a mixture thereof, or a pharmaceutically acceptable salt thereof, that inhibits voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing the compounds of the present invention. Also further provided is an atropi-selective preparation of said compounds of Formula (I), and intermediate thereof.

The present invention relates to novel indanyl urea derivatives of formula (I):their pharmaceutically acceptable salts, and their isomers, steroisomers, atropisomers, conformers, tautomers, polymorphs, hydrates and solvates. The present invention also encompasses process for preparing novel compounds and pharmaceutical composition of said compounds. The invention further relates to the use of the compounds for the preparation of medicament for use as pharmaceuticals.

The present invention relates to novel compounds that can act as antidotes for treating “Acute Cannabinoid Overdose” produced by classical cannabinoids such as Δ9-tetrahydrocannabinol (THC) and several synthetic psychoactive cannabinoids (SPCs). The cannabis constituent THC exerts its psychotropic effects via CB1 receptor activation and SPCs mimic the effects of THC with higher potency and severe neurotoxicity. Compounds disclosed in this invention, their enantiomers, diastereomers, geometric isomers, racemates, tautomers, rotamers, atropisomers, metabolites, N-oxides, salts, solvates, hydrates, isotopic variations and their polymorphic forms can be therapeutically useful in an emergency setting for counteracting the intoxicating effects of acute THC ingestion and SPC overdose. Also, aspects of the invention are concerned with pyrazoles, imidazoles, triazoles, thiazoles, oxazoles, dihydropyrazoles, pyrrolidinones, azetidines, oxyazetidines and azaspiro[3.3]heptanes with unique pharmacokinetic and pharmacodynamic properties for treating “Acute Cannabinoid Overdose”.

The invention relates to a compound for treating thrombotic diseases. Specifically, the invention provides a compound as shown in a formula I, or a pharmaceutically acceptable salt thereof, or an enantiomer thereof, or a diastereoisomer thereof, or an atropisomer thereof, or a raceme thereof, or a polymorphic substance thereof, or a solvate thereof, or an isotope labeled derivative thereof. After the compound disclosed by the invention is specifically combined with an SH3 structural domain protein of Src kinase, the interference integrin alpha IIb beta 3 is combined with the Src kinase, so that signal transduction from outside to inside is selectively inhibited, and the signal transduction from inside to outside is not influenced, so that the compound disclosed by the invention does not influence a normal physiological hemostasis function while resisting thrombus, and avoids side effects, and the compound can become a new generation of effective medicine for preventing and treating thrombus-related cardiovascular and cerebrovascular diseases.

The present invention relates to a bromodomain inhibitor. Provided are a compound represented by general formula I or a pharmaceutically acceptable salt, enantiomer, diastereomer, atropisomer, racemate, polymorph, solvate, or isotopically labeled compound (including deuterium substitution) thereof, a preparation method of the same, a pharmaceutical composition comprising the same, and a pharmaceutical use thereof.